Table 1 Characteristics of patients in the development and validation cohorts

Patients (n)

116

67

Lesions (n)

124

72

Age (years)

71.27 ± 8.50

71.73 ± 8.53

Prostate volume (mL)

61.56 ± 35.14

59.26 ± 27.42

PSA (ng/mL)

19.37 ± 20.45

22.12 ± 29.70

PSAD (ng/mL/cm³)

0.38 ± 0.44

0.43 ± 0.59

PCa, n (%)

71 (57.3)

43 (59.7)

csPCa, n (%)

55 (44.4)

37 (51.4)

MRI T-stage (n)

 T2/T3/T4

63/8/NA

34/8/1

MRI N-stage (n)

 N0/N1

66/5

38/5

MRI M-stage (n)

 M0/M1

69/2

39/4

PI-RADS V2 (n)

 2/3/4/5

27/23/39/35

15/10/27/20

Gleason score, n (%)

 3 + 3 = 6

16 (12.9)

6 (8.3)

 3 + 4 = 7

12 (9.7)

11 (15.3)

 4 + 3 = 7

16 (12.9)

12 (16.7)

 4 + 4 = 8

18 (14.5)

5 (6.9)

 4 + 5 = 9

3 (2.4)

3 (4.2)

 5 + 4 = 9

2 (1.6)

4 (5.6)

 5 + 5 = 10

4 (3.2)

2 (2.8)